Entries by Michael Kuhrt

QIAGEN: Temporary CEO

After the departure of Peer Schatz, Thierry Bernard is taking over as interim Chief Executive Officer at QIAGEN while the molecular diagnostics company is looking for a permanent head.

Oerth Bio: Joint venture CEO

John Dombrosky is taking over the helm of the newly founded Oerth Bio, a targeted protein degradation joint venture launched by Bayer and US biotech Arvinas.

Solentim: Blending biology and business

It is a brand-new role at Bournemouth-based Life Sciences company Solentim: Mark Stockdale will join the global leader in cell line development instrumentation as as Amalgamator of Business and Biology.

Patrice Ferrand named new Biom’up CEO

Biom’up SA, specialising in surgical hemostasis, appointed Patrice Ferrand as their new CEO. Ferrand replaces Jan Ohrstrom, who was appointed CEO since May and remains Chairman of the Board.

H.E.L. Group: Realising market potential

H.E.L. Group Ltd has a new CEO: The global manufacturer of laboratory tools for process optimisation, safety and scale-up announced the appointment of Louise Madden as Chief Executive Officer.

Jane Osbourn joins Mogrify Board

British cell therapy expert Mogrify Ltd has appointed Jane Osbourn as Chair of the Board. Osbourn will also become a Member of the Scientific Advisory Board and support Mogrifiy’s executive team in therapeutic programme selection, industrial partner development, mentoring and investor relations.

PDC*line Pharma welcomes Dr Channa Debruyne

PDC*line Pharma, a clinical stage biotech company developing a new class of immunotherapies for cancers announced today that Dr Channa Debruyne joined the company in August as medical director to lead the clinical research team.

Avillion appoints Dr Anders Gersel Pedersen

Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates, has announced the appointment of Dr Anders Gersel Pedersen as a Non-Executive Director of Bond 2 Development 2 GP, the General Partner of Bond Avillion 2, the Avillion entity that enters into the co-development agreements with pharma partners.